1-(吡啶-2-基)-2-丁酮 | 6303-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-(吡啶-2-基)-2-丁酮
• 英文名称: 1-(2-Pyridyl)-butan-2-on
• 英文别名: 1-(pyridin-2-yl)-butan-2-one；1-(Pyridin-2-yl)butan-2-one；1-pyridin-2-ylbutan-2-one
• CAS: 6303-73-7
• 化学式: C₉H₁₁NO
• 分子量: 149.192
• InChiKey: YUNKBRZOUZPKPL-UHFFFAOYSA-N

物化性质

• 沸点：
  80-90 °C(Press: 2 Torr)
• 密度：
  1.024±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(吡啶-2-基)-2-丁酮 在 盐酸羟胺 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 1.0h， 以89%的产率得到1-methyl-8-(pyridin-2-yl)-3,6-diazahomoadamantan-9-one oxime
  参考文献：
  名称：

  Synthesis of 1-methyl-8-(pyridin-2-yl)-3,6-diazahomoadamantane and its derivatives

  摘要：

  Condensation of 1-(pyridin-2-yl)butan-2-one with 1,3,6,8-tetraazatricyclo[4.4.1.13, 8]dodecane gave 1-methyl-8-(pyridin-2-yl)-3,6-diazahomoadamantan-9-one as intermediate product in the synthesis of 1-methyl-8-(pyridin-2-yl)-3,6-diazahomoadamantane and its derivatives with various functional groups at the bridging carbon atom.

  DOI：

  10.1134/s1070428010100155
• 作为产物：
  描述：

  碳酸甲丙酯 在 乙醚 、 苯基锂 作用下， 生成 1-(吡啶-2-基)-2-丁酮
  参考文献：
  名称：

  The Synthesis of Heterocyclic Nitrogen-containing Ketones. I. Ketones Derived from 2-Picoline

  摘要：

  DOI：

  10.1021/ja01153a081

文献信息

• [EN] SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2017044434A1

  公开（公告）日：2017-03-16

  The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

  本发明提供了新颖的杂环芳基化合物，其药用盐和制剂。它们在预防、管理、治疗或减轻蛋白激酶介导的疾病的严重程度方面具有用处。该发明还提供了包括这些化合物的药用组合物以及使用这些组合物治疗蛋白激酶介导的疾病的方法。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。
• [EN] QUINOLINE DERIVATIVES AS PIK3 INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE EN TANT QU'INHIBITEURS DE PI3K
  申请人：AMGEN INC

  公开号：WO2012068343A1

  公开（公告）日：2012-05-24

  Substituted bicyclic heteroaryls having the general formula (I) and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p1 108 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML), Myelodysplastic syndrome (MDS), myeio-proiiferative diseases (MPD), Chronic Myeloid Leukemia (CML), T-cell Acute Lymphoblastic leukaemia (T-ALL), B-cell Acute Lymphoblastic leukaemia (B-ALL), Non Hodgkins Lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.

  具有通用公式（I）的取代的双环杂环芳基化合物及含有它们的组合物，用于治疗一般性炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、牛皮癣、伴有炎症成分的皮肤问题、慢性炎症性疾病，包括但不限于自身免疫性疾病如系统性红斑狼疮（SLE）、重症肌无力、类风湿性关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化、干燥综合征和自身免疫性溶血性贫血，包括所有形式的过敏症状。本发明还提供了治疗通过或与p1108活性介导、依赖或相关联的癌症的方法，包括但不限于白血病，如急性髓系白血病（AML）、骨髓增生异常综合征（MDS）、骨髓增殖性疾病（MPD）、慢性髓系白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和固体肿瘤，如乳腺癌。
• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Bui Minna

  公开号：US20100331306A1

  公开（公告）日：2010-12-30

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有替代双环杂环芳基的化合物及其组合物，用于治疗一般性炎症、关节炎、风湿性疾病、骨关节炎、炎性肠道疾病、炎性眼部疾病、炎性或不稳定膀胱疾病、牛皮癣、具有炎症成分的皮肤疾病、慢性炎症症状，包括但不限于自身免疫疾病如系统性红斑狼疮（SLE）、重症肌无力、类风湿关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化、Sjogren综合症和自身免疫性溶血性贫血，包括各种过敏症状。本发明还提供了一种治疗与p110δ活性有关、依赖于或相关的癌症的方法，包括但不限于白血病，如急性髓细胞白血病（AML）、髓增生异常综合征（MDS）、髓增生性疾病（MPD）、慢性髓细胞白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体瘤，如乳腺癌。
• Amine derivatives
  申请人：Bionomics Limited

  公开号：EP2524912A1

  公开（公告）日：2012-11-21

  The present invention relates to Kv1.3 potassium channel blockers of Formula (I) and their use in the treatment of autoimmune and inflammatory diseases.

  本发明涉及公式（I）的Kv1.3钾通道阻滞剂及其在治疗自身免疫和炎症性疾病中的应用。